TVTX
Travere Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$52.42
+6.09%Margins
Gross margin
94.7%
EBITDA margin
-15.1%
EBIT margin
-20.5%
Net margin
-18.7%
FCF margin
20.8%
-538.0%
Return on equity
-14.3%
Return on assets
-20.9%
Return on invested capital
0.79x
Asset turnover
$176.6M
Cash from operations
$4.92
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Sep 1, 2026